贝伐单抗联合肝动脉化疗栓塞治疗原发性肝癌的 Meta分析

doi:10.3969/j.issn.1000-8535.2020.03.020

摘要/Abstract

摘要： 目的评价贝伐单抗联合肝动脉化疗栓塞治疗原发性肝癌的疗效及不良反应。方法 2名评价员通过独立地检索中英文数据库,纳入随机对照研究,其中治疗组为肝动脉灌注贝伐单抗联合肝动脉化疗栓塞组、对照组为单独肝动脉化疗栓塞组,并通过Jadad量表对纳入文献质量进行评分,最后采用Review Manager 5.2软件进行Meta分析。结果纳入6篇文献,466例病例。结果显示:在疗效方面,治疗组的3、6个月疾病有效率及疾病控制率,12个月的生存率均高于对照组且差异有统计学意义(P<0.05);在安全性方面,两组间关于发热、转氨酶升高、恶心、黑便的发生率之间的比较无统计学意义(P＞0.05)。结论肝动脉灌注贝伐单抗联合肝动脉化疗栓塞治疗原发性肝癌与单独肝动脉化疗栓塞比较,能有效提高肝癌患者近期及远期疗效,且并不增加不良反应发生率。

关键词: 贝伐单抗, 肝动脉化疗栓塞, 原发性肝癌, Meta分析

Abstract: Objective To evaluate the efficacy and side effects of bevacizumab combined with thanscatheter artierial chemoembolzation in the treatment of primary liver cancer. Methods Two reviewers collected data about clinical trials that the combination of bevacizumab and thanscatheter artierial chemoembolzation for treatment of primary liver cancer from data bases. Jadad Score and Review Manager 5.2 software were respectively used to assess the quality of included studies and analyze the obtained data. Results Six randomized controlled trials involving 466 patients were included in this paper. The results of the meta-analysis showed that compared with thanscatheter artierial chemoembolzation group alone, bevacizumab combined with thanscatheter artierial chemoembolzation improved the response rate and disease control rate, prolonged 12 month survival rate (P<0.05). As for side effects, there were no statistically different of those about fever, level of transaminase, nausea and melena between two groups(P>0.05). Conclusion Compared with simple thanscatheter artierial chemoembolzation group, and Bevacizumab combined with thanscatheter artierial chemoembolzation group, the later may improve short-term and long-term effects, and side effects were under control.

Key words: Bevacizumab, Thanscatheter artierial chemoembolzation, Primary liver cancer, Meta analysis

林晓纯, 林坤鹏, 林纯旋. 贝伐单抗联合肝动脉化疗栓塞治疗原发性肝癌的 Meta分析[J]. 广州医药, 2020, 51(3): 86-92.

LIN Xiaochun, LIN Kunpeng, LIN Chunxuan. Efficacy of Bevacizumab combined with thanscatheter artierial chemoembolzation for treating primary liver cancer: Meta analysis[J]. Guangzhou Medical Journal, 2020, 51(3): 86-92.

参考文献

[1] FENG R M, ZONG Y N, CAO S M, et al. Currentcancer situation in China: good or bad news from the 2018 Global Cancer Statistics? [J]. Cancer Commun (Lond), 2019, 39(1): 22.
[2] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[3] MATTIUZZI C, LIPPI G. Current Cancer Epidemiology[J]. Epidemiol Glob Health, 2019,9(4):217-222.
[4] BRUIX J, SHERMAN M. Management of hepatocellular carcinoma[J]. Hepatol, 2005(42): 1208-1236.
[5] SARASWAT V A, PANDEY G, SHETTY S. Treatment algorithms for managing hepatocellular carcinoma[J]. J Clin Exp Hepatol, 2014, 4(Suppl 3): S80-89.
[6] GEORGIADES C S, HONG K, GESCHWIND J F. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma[J]. Cancer J, 2008, 14(2): 117-122.
[7] FINN R S, ZHU A X. Targeting angiogenesis in hepatocellular cancer: focus on VEGF and bevacizumab[J]. Expert Rev Anticancer Ther, 2009(9): 503-509.
[8] LI X, FENG G S, ZHENG C S, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level[J]. World J Gastroenterol, 2004,(10): 2878-2882.
[9] ROVIELLO G, BACHELOT T, HUDIS C A, et al. The role of bevacizumab in solid tumours: a literature based meta-analysis of randomised trials[J]. Eur J Cancer, 2017(75): 245-258.
[10] FLORESCU-TENEA R M, KAMAL A M, ITRUT P M, et al. Colorectal Cancer: an update on treatment options and future perspectives[J]. Curr Health Sci J, 2019, 45(2): 134-141.
[11] CONG J, LIU R, HOU J, et al. Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer[J]. J BUON, 2019, 24(3): 1003-1008.
[12] JADAD A R, MOORE R A, CARROLL D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary[J]. Control Clin Trials, 1996, 17(1): 1-12.
[13] 马红丹, 万灵侠, 王春燕. 贝伐单抗联合肝动脉化疗栓塞术治疗原发性肝癌疗效分析[J]. 医药论坛杂志, 2016, 37(10): 129-131.
[14] 赵灵华, 曾斌. 贝伐单抗联合肝动脉化疗栓塞术治疗原发性肝癌的临床疗效及安全性评[J]. 中国临床药理学杂志, 2016, 32(2): 126-128.
[15] 曾筱怡, 邱金宝, 陈林.贝伐单抗联合肝动脉化疗栓塞术对36 例晚期原发性肝癌生存预后的影响分析[J]. 药物临床杂志, 2016, 37(19): 20-23,57.
[16] 孙健. 贝伐单抗联合肝动脉化疗栓塞术对原发性肝癌患者生存期的影响研究[J]. 医药天地杂志, 2018, 15(8): 76-77.
[17] 孙健铭, 杨彦林, 王继光. 贝伐单抗联合TACE治疗原发性肝癌近远期疗效评价[J]. 实用药物与临床杂志, 2018, 21(10): 1120-1123.
[18] 岳希鹏, 李瀛, 别良玉, 等. 贝伐单抗对接受TACE治疗的晚期肝癌患者疗效的影响[J]. 河南医学研究杂志, 2018, 27(24): 4439-4442.
[19] BRUIX J, SHERMAN M. Practice guidelines committee, American association for the study of liver diseases. management of hepatocellular carcinoma[J]. Hepatol, 2005(42): 1208-1236.
[20] 钱骏, 冯敢生. 原发性肝癌的综合介入治疗[J]. 中华肿瘤杂志, 2003, 25(5): 417-420.
[21] XIAO E H, GUO D, BIAN D J. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells[J]. World J Gastroenterol, 2009(15): 4582-4586.
[22] NAHM J H, RHEE H, KIM H, et al. Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: a biopsy and resection matched study[J]. Oncotarget, 2017(8): 99359-99371.
[23] SAKURAI Y, OHGIMOTO K, KATAOKA Y. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice[J]. Proc Natl Acad Sci USA, 2005, 102(4): 1076-1081.
[24] FERNÁNDEZ M, SEMELA D, BRUIX J, et al. Angiogenesis in liver disease[J]. Hepatol, 2009(50): 604-620.
[25] PANG R, POON R T. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma[J]. Cancer Lett, 2006, 242(2): 151-167.
[26] VIVEIROS P, RIAZA, LEWANDOWSKI R J, et al. Current state of liver directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC) [J]. Cancers (Basel), 2019, 11(8): E1085.
[27] ZHAN P, QIAN Q, YU L K. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis[J]. Hepatobiliary Surg, 2013(2): 209-215.
[28] KUDO M, UESHIMA K, TORIMURA T, et al. Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Clin Oncol, 2018(36): 206.
[29] SHOJI T, ETO H, SATO T, et al. A new therapeutic strategy for recurrent ovarian cancer-bevacizumab beyond progressive disease[J]. Healthcare (Basel), 2019, 7(3): E109.
[30] SPENCER P H,BISHAL G,ELVIRA D, et al. A systematic review and meta-analysis of bevacizumab in first-line metastatic breast cancer: lessons for the research and regulatory enterprises[J]. Natl Cancer, 2020,112(4): djz211.
[31] BUIJS M, REYES D K, PAWLIK T M, et al. Phase 2 trial of concurrent Bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma[J]. Cancer, 2013, 119(5): 1042-1049.
[32] WANG J K, ZHOU Y Y, GUO S J, et al. Cetuximab conjugated and doxorubicin loaded silica nanoparticles for tumor-targeting and tumor microenvironment responsive binary drug delivery of liver cancer therapy[J]. Mate Sci Eng C, 2017(76): 944-950.
[33] BRITTEN C D, GOMES A S, WAINBERG Z A, et al. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study[J]. BMC Cancer, 2012(1): 12-16.
[34] PINTER M, ULBRICH G, SIEGHART W, et al. Hepatocellular carcinoma:a phase ii randomized controlled double blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo[J]. Radiol, 2015, 277(3): 903-912.